THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST

Their core work

Newcastle upon Tyne Hospitals NHS Foundation Trust is one of the largest NHS teaching hospital trusts in the UK, providing acute and specialist clinical services across the North East of England. Within EU research, they contribute real-world clinical data, patient cohorts, and hospital-based expertise to health research consortia — particularly in rare diseases, medication safety, and digital health outcomes. Their role is that of a clinical site and data provider, bridging the gap between laboratory research and actual patient care in areas like pharmacovigilance, molecular diagnostics, and mobility assessment in ageing populations.

What they specialise in

How they've shifted over time

In their earlier H2020 involvement (2017-2019), NUTH focused on rare diseases and orphan drug repurposing, contributing to clinical trials for skeletal dysplasia and building rare disease data infrastructure through EJP RD. From 2019 onward, their focus shifted decisively toward digital health, real-world data collection, and precision diagnostics — joining projects on pregnancy pharmacovigilance (ConcePTION), digital mobility outcomes (MOBILISE-D), and RNA-based molecular diagnosis (DIAMONDS). The trajectory shows a clear move from niche rare disease work toward broader data-driven and digital approaches to clinical care.

NUTH is moving toward data-intensive, digitally-enabled clinical research — expect growing capacity in real-world evidence generation, biobanking, and molecular diagnostics.

How they like to work

NUTH has never coordinated an H2020 project — they join as a participant or third-party contributor, providing clinical infrastructure and patient access rather than leading research design. With 254 unique consortium partners across 41 countries, they operate within very large pan-European consortia (EJP RD alone involves dozens of partners). This makes them a reliable, low-friction clinical partner: they bring hospital-level data and patient populations without competing for scientific leadership.

NUTH has collaborated with 254 unique partners across 41 countries, reflecting their presence in large-scale European health consortia. Their network is broad rather than deep, spanning most EU member states and associated countries through flagship programmes like EJP RD and ConcePTION.

What sets them apart

As a major NHS teaching hospital, NUTH offers something most academic partners cannot: direct access to large, diverse patient populations within an active clinical care setting. This is critical for projects needing real-world clinical validation, longitudinal patient data, or biobank samples. For consortium builders, NUTH provides a trusted UK clinical site with experience across rare diseases, pharmacovigilance, and digital health outcomes — and a track record of delivering within large EU consortia.

Highlights from their portfolio

• ConcePTION
  Largest funded project (EUR 602,464), building a Europe-wide ecosystem for monitoring medication safety during pregnancy — a critical and underserved area.
• DIAMONDS
  Most recent project (2020-2026), applying RNA personalised molecular signatures to diagnose febrile illness — represents NUTH's move into precision diagnostics.
• EJP RD
  Part of the European Joint Programme on Rare Diseases, one of the largest coordinated rare disease initiatives in Europe with massive consortium reach.